Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (3)
Early P 1 (1)
P 1 (8)
P 2 (6)
P 3 (1)
P 4 (1)

Trial Status

Recruiting8
Completed4
Not Yet Recruiting3
Active Not Recruiting2
Unknown2
Terminated2

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07564466Phase 2Not Yet RecruitingPrimary

A Study of SKB571 in Participants With Gastrointestinal Tumors

NCT07406633Phase 2Recruiting

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

NCT06263205Not ApplicableCompletedPrimary

Non-Dressing vs. Routine Dressing Change After Gastrointestinal Cancer Surgery

NCT07279428Phase 1RecruitingPrimary

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT03833700Phase 1Active Not Recruiting

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

NCT07232407Phase 1RecruitingPrimary

A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT07104877Not ApplicableActive Not Recruiting

A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

NCT05981235Phase 1CompletedPrimary

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

NCT07067385Phase 1Recruiting

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

NCT06478030RecruitingPrimary

Combined Screening for Gastrointestinal Tumors

NCT04171141Phase 1TerminatedPrimary

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

NCT06775080Phase 2RecruitingPrimary

The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors

NCT06755242Phase 1Not Yet RecruitingPrimary

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT04629326Not ApplicableRecruitingPrimary

PD-L1 Targeting Molecular Imaging of Solid Tumors

NCT06152757Early Phase 1RecruitingPrimary

BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

NCT05262335Phase 2UnknownPrimary

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)

NCT06085365Phase 3UnknownPrimary

Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors

NCT05922358Phase 2Not Yet RecruitingPrimary

Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

NCT01648465Phase 2TerminatedPrimary

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

NCT01552291Phase 4Completed

The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies

Scroll to load more

Research Network

Activity Timeline